The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Gain-of-function mutant p53 in cancer progression and therapy
Open accessAbstract
p53 is a key tumor suppressor, and loss of p53 function is frequently a prerequisite for cancer development. The p53 gene is the most frequently mutated gene in human cancers; p53 mutations occur in >50% of all human cancers and in almost every type of human cancers. Most of p53 mutations in cancers are missense mutations, which produce the full-length mutant p53 (mutp53) protein with only one amino acid difference from wild-type p53 protein. In addition to loss of the tumor-suppressive function of wild-type p53, many mutp53 proteins acquire new oncogenic activities independently of wild-type p53 to promote cancer progression, termed gain-of-function (GOF). Mutp53 protein often accumulates to very high levels in cancer cells, which is critical for its GOF. Given the high mutation frequency of the p53 gene and the GOF activities of mutp53 in cancer, therapies targeting mutp53 have attracted great interest. Further understanding the mechanisms underlying mutp53 protein accumulation and GOF will help develop effective therapies treating human cancers containing mutp53. In this review, we summarize the recent advances in the studies on mutp53 regulation and GOF as well as therapies targeting mutp53 in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
p53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710
The P53 pathway: what questions remain to be explored?
Levine, A. J., Hu, W., & Feng, Z. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401910 · Cited by 659
Self-citationUSP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 2×
“The overexpression of USP10 in p53-mutant RCCs inhibits MDM2-mediated mutp53 ubiquitination, leading to mutp53 accumulation (Yuan et al., 2010).”
BackgroundMilner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
Kieser, A., Weich, H. A., Brandner, G., Marmé, D., & Kölch, W. (1994) · PubMed · Cited by 511
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations
Merkle, F. T., Ghosh, S., Kamitaki, N., Mitchell, J., Avior, Y., Mello, C., Kashin, S., Mekhoubad, S., Ilic, D., Charlton, M., et al. (2017) · Nature · doi:10.1038/nature22312 · Cited by 506
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth
Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M., Patel, K. M., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 482
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 2×
“Mutp53 sequesters p73 from forming the complex with NF-Y, activating PDGF receptor b (PDGFRb) signaling to promote pancreatic cancer metastasis (Weissmueller et al., 2014).”
BackgroundCooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Self-citationp53 and its mutants in tumor cell migration and invasion
Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
Tumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434
Self-citationParkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431
Self-citationDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Contribution of p53 to Metastasis
Powell, E., Piwnica-Worms, D., & Piwnica-Worms, H. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0136 · Cited by 355
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Self-citationDong, P., Karaayvaz, M., Jia, N., Kaneuchi, M., Hamada, J., Watari, H., Sudo, S., Ju, J., & Sakuragi, N. (2013) · Oncogene · doi:10.1038/onc.2012.334 · Cited by 307
Tumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
Self-citationLi, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Hanel, W., Marchenko, N., Xu, S., Xiaofeng Yu, S., Weng, W., & Moll, U. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.17 · Cited by 283
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 275
Verduci, L., Ferraiuolo, M., Sacconi, A., Ganci, F., Vitale, J., Colombo, T., Paci, P., Strano, S., Macino, G., Rajewsky, N., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1368-y · Cited by 267
Wang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. Y.-H. P., & Zhu, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.001 · Cited by 250
Mutant p53 in cancer therapy—the barrier or the path
Zhou, X., Hao, Q., & Lu, H. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 245
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Milner, J., Medcalf, E. A., & Cook, A. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243
Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Parrales, A., Ranjan, A., Iyer, S. V., Padhye, S., Weir, S. J., Roy, A., & Iwakuma, T. (2016) · Nature Cell Biology · doi:10.1038/ncb3427 · Cited by 239
Schulz-Heddergott, R., Stark, N., Edmunds, S. J., Li, J., Conradi, L.-C., Bohnenberger, H., Ceteci, F., Greten, F. R., Dobbelstein, M., & Moll, U. M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.004 · Cited by 238
Gualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 237
Zhou, G., Wang, J., Zhao, M., Xie, T.-X., Tanaka, N., Sano, D., Patel, A. A., Ward, A. M., Sandulache, V. C., Jasser, S. A., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.024 · Cited by 235
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Heese, C., & Pedersen, P. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22776 · Cited by 231
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Control of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 219
Links between mutant p53 and genomic instability
Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression
Liu, J., Zhang, C., Zhao, Y., Yue, X., Wu, H., Huang, S., Chen, J., Tomsky, K., Xie, H., Khella, C. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01947-w · Cited by 213
Self-citationChaperone-mediated autophagy degrades mutant p53
Vakifahmetoglu-Norberg, H., Kim, M., Xia, H.-G., Iwanicki, M. P., Ofengeim, D., Coloff, J. L., Pan, L., Ince, T. A., Kroemer, G., Brugge, J. S., et al. (2013) · Genes & Development · doi:10.1101/gad.220897.113 · Cited by 203
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Di Agostino, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 201
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis
Fontemaggi, G., Dell'Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., Terrenato, I., Mottolese, M., Muti, P., Domany, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1669 · Cited by 195
YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins
Di Agostino, S., Sorrentino, G., Ingallina, E., Valenti, F., Ferraiuolo, M., Bicciato, S., Piazza, S., Strano, S., Del Sal, G., & Blandino, G. (2016) · EMBO reports · doi:10.15252/embr.201540488 · Cited by 193
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion
Muller, P. A. J., Trinidad, A. G., Timpson, P., Morton, J. P., Zanivan, S., van den Berghe, P. V. E., Nixon, C., Karim, S. A., Caswell, P. T., Noll, J. E., et al. (2013) · Oncogene · doi:10.1038/onc.2012.148 · Cited by 192
Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191
Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization
Peng, Y., Chen, L., Li, C., Lu, W., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102817200 · Cited by 183
Geldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 178
The regulation of MDM2 oncogene and its impact on human cancers
Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 173
Self-citationBlagosklonny, M. V. (2000) · The FASEB Journal · doi:10.1096/fj.99-1078rev · Cited by 170
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
Di Minin, G., Bellazzo, A., Dal Ferro, M., Chiaruttini, G., Nuzzo, S., Bicciato, S., Piazza, S., Rami, D., Bulla, R., Sommaggio, R., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.10.013 · Cited by 162
Kogan-Sakin, I., Tabach, Y., Buganim, Y., Molchadsky, A., Solomon, H., Madar, S., Kamer, I., Stambolsky, P., Shelly, A., Goldfinger, N., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.94 · Cited by 161
Mechanical cues control mutant p53 stability through a mevalonate–RhoA axis
Ingallina, E., Sorrentino, G., Bertolio, R., Lisek, K., Zannini, A., Azzolin, L., Severino, L. U., Scaini, D., Mano, M., Mantovani, F., et al. (2017) · Nature Cell Biology · doi:10.1038/s41556-017-0009-8 · Cited by 161
Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 157
MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function
Donzelli, S., Fontemaggi, G., Fazi, F., Agostino, S. D., Padula, F., Biagioni, F., Muti, P. C., Strano, S., & Blandino, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.190 · Cited by 154
Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53Preprint
Pfister, N. T., & Prives, C. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026054 · Cited by 151
Amelio, I., Mancini, M., Petrova, V., Cairns, R. A., Вихрева, П. Н., Nicolai, S., Marini, A., Antonov, A. A., Quesne, J. P. C. L., Acevedo, J. D. B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808314115 · Cited by 144
Liu, J., Zhang, C., Zhao, Y., & Feng, Z. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25609 · Cited by 143
Self-citationMutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
Cordani, M., Oppici, E., Dando, I., Butturini, E., Dalla Pozza, E., Nadal-Serrano, M., Oliver, J., Roca, P., Mariotto, S., Cellini, B., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.001 · Cited by 141
TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity
Tomasini, R., Tsuchihara, K., Tsuda, C., Lau, S. K., Wilhelm, M., Rufini, A., Tsao, M., Iovanna, J., Jurisicova, A., Melino, G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812096106 · Cited by 132
Rodriguez, O. C., Choudhury, S., Kolukula, V. K., Vietsch, E. E., Catania, J., Preet, A., Reynoso, K., Bargonetti, J., Wellstein, A., Albanese, C., et al. (2012) · Cell Cycle · doi:10.4161/cc.22778 · Cited by 129
Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
Wiech, M., Olszewski, M. B., Tracz-Gaszewska, Z., Wawrzynow, B., Zylicz, M., & Zylicz, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051426 · Cited by 129
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels
Novo, D., Heath, N., Mitchell, L. E., Caligiuri, G., MacFarlane, A., Reijmer, D., Charlton, L., Knight, J. R. P., Calka, M., McGhee, E. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07339-y · Cited by 129
Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities
Kollareddy, M., Dimitrova, E., Vallabhaneni, K. C., Chan, A., Le, T., Chauhan, K. M., Carrero, Z. I., Ramakrishnan, G., Watabe, K., Haupt, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms8389 · Cited by 127
Wang, W., Cheng, B., Miao, L., Mei, Y., & Wu, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.97 · Cited by 127
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer
Silva, J. L., Cino, E. A., Soares, I. N., Ferreira, V. F., & de Oliveira, G. A. P. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00473 · Cited by 121
Multiple Stress Signals Activate Mutant p53 In Vivo
Suh, Y., Post, S. M., Elizondo-Fraire, A. C., Macció, D. R., Jackson, J. G., El‐Naggar, A. K., Pelt, C. V., Terzian, T., & Lozano, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0459 · Cited by 120
Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers
Solomon, H., Dinowitz, N., Pateras, I. S., Cooks, T., Shetzer, Y., Molchadsky, A., Charni‐Natan, M., Rabani, S., Koifman, G., Tarcic, O., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0060-8 · Cited by 119
Masciarelli, S., Fontemaggi, G., Di Agostino, S., Donzelli, S., Carcarino, E., Strano, S., & Blandino, G. (2014) · Oncogene · doi:10.1038/onc.2013.106 · Cited by 118
Puca, R., Nardinocchi, L., Porru, M., Simon, A. J., Rechavi, G., Leonetti, C., Givol, D., & D’Orazi, G. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15642 · Cited by 117
Liao, P., Zeng, S. X., Zhou, X. Y., Chen, T., Zhou, F., Cao, B., Jung, J. H., Sal, G. D., Luo, S., & Lu, H. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.006 · Cited by 115
Neilsen, P. M., Noll, J. E., Suetani, R. J., Schulz, R. B., Al‐Ejeh, F., Evdokiou, A., Lane, D. P., & Callen, D. F. (2011) · Oncotarget · doi:10.18632/oncotarget.382 · Cited by 113
Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W. (2013) · Nature Communications · doi:10.1038/ncomms3996 · Cited by 112
Self-citationGenomic instability in mutant p53 cancer cells upon entotic engulfment
Mackay, H. L., Moore, D. A., Hall, C., Birkbak, N. J., Jamal‐Hanjani, M., Karim, S. A., Phatak, V. M., Piñon, L., Morton, J. P., Swanton, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05368-1 · Cited by 111
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
Stojanovic, N., Hassan, Z., Wirth, M., Wenzel, P., Beyer, M., Schäfer, C., Brand, P., Kroemer, A., Stauber, R. H., Schmid, R. M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.344 · Cited by 110
Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., Dasmahapatra, B., & Weller, M. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402301 · Cited by 108
Zhang, C., Liu, J., Zhao, Y., Yue, X., Zhu, Y., Wang, X., Wu, H., Blanco, F., Li, S., Bhanot, G., et al. (2016) · eLife · doi:10.7554/elife.10727 · Cited by 108
Self-citationThe mutant p53‐ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1
Pruszko, M., Milano, E., Forcato, M., Donzelli, S., Ganci, F., Agostino, S. D., Panfilis, S. D., Fazi, F., Bates, D. O., Bicciato, S., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643370 · Cited by 107
Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide
Wang, X., Chen, J., Liu, J., You, C., Liu, Y., & Mao, Q. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3380-0 · Cited by 106
Self-citationPla2g16 phospholipase mediates gain-of-function activities of mutant p53
Xiong, S., Tu, H., Kollareddy, M., Pant, V., Li, Q., Zhang, Y., Jackson, J. G., Suh, Y., Elizondo-Fraire, A. C., Yang, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404139111 · Cited by 106
Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α
Basu, S., Gnanapradeepan, K., Barnoud, T., Kung, C.-P., Tavecchio, M., Scott, J., Watters, A., Chen, Q., Kossenkov, A. V., & Murphy, M. E. (2018) · Genes & Development · doi:10.1101/gad.309062.117 · Cited by 102
Aggarwal, M., Saxena, R., Sinclair, E., Fu, Y., Jacobs, A., Dyba, M., Wang, X., Cruz, I., Berry, D., Kallakury, B., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.48 · Cited by 101
Li, D., Yallowitz, A. R., Ozog, L. S., & Marchenko, N. D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.158 · Cited by 101
Xu, J., Wang, J., Hu, Y., Qian, J., Xu, B., Chen, H., Zou, W., & Fang, J.-Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.75 · Cited by 101
Gurtner, A., Starace, G., Norelli, G., Piaggio, G., Sacchi, A., & Bossi, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094813 · Cited by 92
Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ
Escoll, M., Gargini, R., Cuadrado, A., Antón, I. M., & Wandosell, F. G. (2017) · Oncogene · doi:10.1038/onc.2016.518 · Cited by 92
Murphy, K. L., Dennis, A. P., & Rosen, J. M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0128com · Cited by 91
Alam, S. K., Yadav, V. K., Bajaj, S., Datta, A., Dutta, S. K., Bhattacharyya, M., Bhattacharya, S., Debnath, S., Roy, S., Boardman, L. A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.133 · Cited by 91
USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
Padmanabhan, A., Candelaria, N., Wong, K.-K., Nikolai, B. C., Lonard, D. M., O’Malley, B. W., & Richards, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-03599-w · Cited by 88
Loizou, E., Banito, A., Livshits, G., Ho, Y.-J., Koche, R. P., Sánchez-Rivera, F. J., Mayle, A., Chen, C.-C., Kinalis, S., Bagger, F. O., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1391 · Cited by 88
Hong, B., Prabhu, V. V., Zhang, S., van den Heuvel, A. P. J., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0955 · Cited by 87
Polotskaia, A., Xiao, G., Reynoso, K., Martin, C., Qiu, W., Hendrickson, R. C., & Bargonetti, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416318112 · Cited by 85
Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors
Blagosklonny, M. V., Trostel, S. Y., Kayastha, G., Demidenko, Z. N., Vassilev, L. T., Romanova, L. Y., Bates, S. E., & Fojo, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3433 · Cited by 84
BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function
Yue, X., Zhao, Y., Liu, J., Zhang, C., Yu, H., Wang, J., Zheng, T., Liu, L., Li, J., Feng, Z., et al. (2015) · eLife · doi:10.7554/elife.08401 · Cited by 84
Self-citationHiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
He, C., Li, L., Guan, X., Li, X., & Miao, X. (2016) · Chemotherapy · doi:10.1159/000446361 · Cited by 81
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05435-1 · Cited by 77
Ubertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75
Gambogic acid‐induced degradation of mutant p53 is mediated by proteasome and related to CHIP
Wang, J., Zhao, Q. J., Qi, Q., Gu, H.-Y., Rong, J., Mu, R., Zou, M., Tao, L., You, Q., & Guo, Q. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22941 · Cited by 69
Pourebrahim, R., Zhang, Y., Liu, B., Gao, R., Xiong, S., Lin, P. P., McArthur, M. J., Ostrowski, M. C., & Lozano, G. (2017) · Genes & Development · doi:10.1101/gad.304972.117 · Cited by 64
Common genetic variants in the TP53 pathway and their impact on cancer
Barnoud, T., Parris, J. L. D., & Murphy, M. E. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz052 · Cited by 64
Will, K., Warnecke, G., Wiesmüller, L., & Deppert, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13681 · Cited by 61
Mutant p53 and mTOR/PKM2 regulation in cancer cells
Dando, I., Cordani, M., & Donadelli, M. (2016) · IUBMB Life · doi:10.1002/iub.1534 · Cited by 57
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Meng, X., Bi, J., Li, Y., Yang, S., Zhang, Y., Li, M., Liu, H., Li, Y., McDonald, M. E., Thiel, K. W., et al. (2018) · Cancers · doi:10.3390/cancers10050149 · Cited by 57
Yan, W., Jung, Y.-S., Zhang, Y., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103497 · Cited by 55
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
Sonego, M., Schiappacassi, M., Lovisa, S., Dall’Acqua, A., Bagnoli, M., Lovat, F., Libra, M., D’Andrea, S., Canzonieri, V., Militello, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201504 · Cited by 55
Shetzer, Y., Molchadsky, A., & Rotter, V. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026203 · Cited by 54
A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models
Zhao, Y., Wu, L., Yue, X., Zhang, C., Wang, J., Li, J., Sun, X., Zhu, Y., Feng, Z., & Hu, W. (2018) · eLife · doi:10.7554/elife.34701 · Cited by 54
Self-citationIt takes a team: a gain-of-function story of p53-R249S
Wang, H., Liao, P., Zeng, S. X., & Lu, H. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy086 · Cited by 54
Zerbini, L. F., Wang, Y., Correa, R. G., Cho, J., & Libermann, T. A. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1966 · Cited by 51
Yue, X., Zhang, C., Zhao, Y., Liu, J., Lin, A. W., Tan, V. M., Drake, J. M., Liu, L., Boateng, M. N., Li, J., et al. (2017) · Genes & Development · doi:10.1101/gad.301564.117 · Cited by 50
Self-citationSmall molecule activators of the p53 response
Ladds, M. J. G. W., & Laín, S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz006 · Cited by 49
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication
Singh, S., Vaughan, C. A., Frum, R. A., Grossman, S. R., Deb, S., & Deb, S. P. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87724 · Cited by 46
Valenti, F., Ganci, F., Fontemaggi, G., Sacconi, A., Strano, S., Blandino, G., & Agostino, S. D. (2015) · Oncotarget · doi:10.18632/oncotarget.2587 · Cited by 45
Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta
Madar, S., Harel, E., Goldstein, I., Stein, Y., Kogan-Sakin, I., Kamer, I., Solomon, H., Dekel, E., Tal, P., Goldfinger, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061353 · Cited by 44
Shetzer, Y., Kagan, S., Koifman, G., Sarig, R., Kogan-Sakin, I., Charni, M., Kaufman, T., Zapatka, M., Molchadsky, A., Rivlin, N., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.57 · Cited by 43
Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53
Zhao, Y., Zhang, C., Yue, X., Li, X., Liu, X. J., Yu, H., Белый, В. А., Yang, Q., Feng, Z., & Hu, W. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.33 · Cited by 42
Self-citationTRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma
Jethwa, A., Slabicki, M. M., Hüllein, J., Jentzsch, M., Dalal, V., Rabe, S., Wagner, L., Walther, T., Klapper, W., MMML Network Project, et al. (2018) · Blood · doi:10.1182/blood-2017-09-806679 · Cited by 38
p53: Its Mutations and Their Impact on Transcription
Vaughan, C. A., Pearsall, I., Yeudall, W. A., Deb, S. P., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_4 · Cited by 37
Rahnamoun, H., Hong, J., Sun, Z., Lee, J. H., Lu, H., & Lauberth, S. M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003387 · Cited by 36
Mutant p53—a potential player in shaping the tumor–stroma crosstalk
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz071 · Cited by 35
Yue, X., Zhao, Y., Huang, G. C., Li, J., Zhu, J., Feng, Z., & Hu, W. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.39 · Cited by 31
Self-citationPolyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro
Chen, Z., Chen, J., Keshamouni, V. G., & Kanapathipillai, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.111 · Cited by 28
The Impact of Mutant p53 in the Non-Coding RNA World
Agostino, S. D. (2020) · Biomolecules · doi:10.3390/biom10030472 · Cited by 28
Frum, R. A., Love, I. M., Damle, P. K., Mukhopadhyay, N. D., Deb, S. P., Deb, S., & Grossman, S. R. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0363 · Cited by 19
Cited by
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Self-citationCuproptosis: p53-regulated metabolic cell death?
Xiong, C., Ling, H., Hao, Q., & Zhou, X. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01125-0 · Cited by 263
Mutations of p53 associated with pancreatic cancer and therapeutic implications
Voutsadakis, I. A. (2021) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2021.25.3.315 · Cited by 75
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
Vodicka, P., Andera, L., Opattova, A., & Vodickova, L. (2021) · Cancers · doi:10.3390/cancers13030479 · Cited by 39
Metadata
- Authors
- Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z.
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-28
- Volume
- 12
- Issue
- 9
- Pages
- 674-687
- ISSN
- 1674-2788 (ISSN-L)
- 1759-4685
- OpenAlex
- W3045935025
- Cited by
- 334
- References
- 155
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.